Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
SCIENTURE (NASDAQ: SCNX) announced issuance of U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective Jan 6, 2026 and expiring Feb 5, 2041. Scienture holds exclusive U.S. commercialization rights under a March 2025 agreement with Summit, which will manufacture and supply the product. REZENOPY™ received FDA approval on Apr 19, 2024 and is the highest-dosage FDA-approved naloxone nasal spray. IQVIA (MAT Sep 2025) reports U.S. naloxone sales of approximately $154 million and 9.3 million units, highlighting the market opportunity.
SCIENTURE (NASDAQ: SCNX) provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, the highest-strength FDA-approved naloxone product. Scienture acquired exclusive U.S. commercialization rights in March 2025 and notes FDA approval occurred on April 19, 2024. IQVIA data (MAT September 2025) shows the U.S. naloxone market at approximately $154 million in annual sales and 9.3 million units annually.
Manufacturing is reported to be on track with product readiness expected in Q1 2026, wholesale loading in Q1 2026, and commercial availability beginning in early Q2 2026.
SCIENTURE (NASDAQ: SCNX) announced a strategic collaboration with BlinkRx to expand national access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026. The U.S. losartan market totals about $245M in annual sales with roughly 71 million prescriptions (IQVIA MAT Sept 2025). BlinkRx reports it helps 52% more patients start therapy and keeps them on medication 40% longer, which Scienture says may increase starts, duration, and affordability for patients needing suspension formulations.
SCIENTURE HOLDINGS (NASDAQ: SCNX) announced management will participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9–10, 2025. Narasimhan Mani, President and co-CEO, will present at 2:00 PM ET on December 9. Shankar Hariharan, Executive Chairman and co-CEO, will join one-on-one investor meetings on December 10. A live webcast of the presentation is available at the conference link and a replay will be posted on the company’s investor site under Events and Presentations. The two-day event features Day 1 webcasts and Day 2 one-on-one investor meetings for pre-qualified investors.
SCIENTURE (NASDAQ: SCNX) reported Q3 2025 results and a business update on November 13, 2025. The company launched Arbli™, the first FDA-approved ready-to-use liquid formulation of losartan, and began commercial sales.
Q3 2025 vs Q3 2024: net revenue rose from ~$65K to $590K, and gross profit increased from ~$4K to $575K. Arbli was added to national payor formularies covering >100 million lives and secured GPO agreements reaching >2,500 institutions (~20% of U.S. institutional market). Post-quarter, the company reduced outstanding debt and reported cash of >$8 million as of November 13, 2025. Management plans a commercial launch of REZENOPY® in Q1 2026.
Scienture (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) oral suspension, 10 mg/mL was added to formularies of key national payors, expanding availability to over 100 million covered lives in the United States.
Arbli is the first FDA‑approved ready‑to‑use oral suspension of losartan potassium. According to IQVIA (MAT June 2025), the U.S. losartan market is approximately $256 million in annual sales with >71 million prescriptions per year, representing a commercial opportunity. The company said plan design and utilization management may affect individual out‑of‑pocket costs.
SCIENTURE (NASDAQ: SCNX) announced the start of commercial sales and fulfillment of initial orders for Arbli™ (losartan potassium) Oral Suspension 10 mg/mL, the first FDA‑approved ready‑to‑use losartan oral suspension.
Key commercial facts: the U.S. losartan market is ~$256M annual sales with ~71M prescriptions (IQVIA, MAT June 2025). Scienture launched a multi‑channel promotional campaign, finalized PBM‑led GPO agreements, and executed multiple GPO contracts expanding access to >2,500 healthcare institutions, with estimated potential penetration of 20% of the U.S. institutional market.
Scienture Holdings (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) Oral Suspension, 10mg/mL is commercially available through full-line wholesalers nationwide as of Oct 16, 2025.
Arbli is described as the first FDA-approved ready-to-use liquid losartan, targeting patients unable to swallow tablets (including elderly and children six and older). The U.S. losartan market is noted at $256M annually with 71M prescriptions, positioning Arbli as a new entrant into the broader hypertension market and a replacement for inconsistent compounded liquids.
SCIENTURE Holdings (NASDAQ: SCNX) announced on October 3, 2025 that it entered an agreement with Arena Finance Markets and Arena Special Opportunities III to fully repay and convert outstanding secured convertible debentures.
The conversion revises the debenture conversion price to $2.4861 per share, results in issuance of common stock to satisfy remaining balances, automatically releases liens and security interests, terminates the debenture documents, and deems obligations paid in full except for limited surviving items.
Company leadership said the action strengthens the balance sheet, eliminates interest-bearing obligations, and supports acceleration of commercial momentum following the first product launch.
Scienture Holdings (NASDAQ: SCNX) has secured multiple Group Purchasing Organization (GPO) agreements for Arbli™ (losartan potassium), expanding access to over 2,500 healthcare institutions, representing ~20% of the U.S. institutional market.
Arbli™ is the first FDA-approved ready-to-use oral suspension of losartan, targeting a $256M annual market with 71M prescriptions. The drug is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients.
The product addresses unmet needs with its liquid formulation, eliminating compounding requirements while offering reduced dosing volume and room temperature storage stability. Arbli™ is protected by two USPTO patents listed in the FDA Orangebook.
FAQ
What is the current stock price of Scienture Holdings (SCNX)?
What is the market cap of Scienture Holdings (SCNX)?
